secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001104659-26-000057
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B
-----------------------------------------------------------------------------

- FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.
- FY 2026 adjusted EBITDA expected >$300M; FY 2025 guidance maintained at >$135M.
- Ended Q4 2025 with >$200M cash; LINZESS list price reduced effective Jan 1, 2026.
- FDA aligned on confirmatory Phase 3 trial design for apraglutide (SBS-IF); trial to start H1 2026.
- Strategic alternatives review ongoing to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/0001104659-26-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/tm2534554d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer